Prime Medicine, Inc.

Overview

- **How the company got here** Prime Medicine was founded in 2019 with the goal of using a groundbreaking gene-editing technology called "prime editing" to create one-time curative genetic therapies. The company's technology is based on research from David Liu and his collaborators, and it aims to make precise changes to DNA without causing double-strand breaks, which are a characteristic of other gene-editing methods. Prime Medicine raised significant private funding in its early years to build its platform and intellectual property. In 2022, the company went public through an initial public offering (IPO), making its shares available for trading on the Nasdaq stock exchange. - **What it actually does** Prime Medicine is a biotechnology company that focuses on developing genetic medicines. These are therapies designed to treat diseases by correcting the underlying genetic cause. Their core technology, called "prime editing," is a sophisticated tool that can precisely alter DNA sequences. Think of it like a highly accurate word processor for DNA, capable of making specific corrections, insertions, or deletions to genetic code. The company's ultimate aim is to create one-time treatments that can potentially cure or significantly improve the lives of patients with serious genetic disorders. As of early 2026, Prime Medicine is still in the development phase and does not yet have any approved products on the market. - **Liver Franchise** Prime Medicine is focusing on developing treatments for genetic liver diseases, which are conditions caused by errors in a person's genes that affect the liver. Two key diseases they are targeting are Wilson Disease and Alpha-1 Antitrypsin Deficiency (AATD). Wilson Disease is a rare disorder where the body can't properly process copper, leading to its buildup in organs like the liver. AATD is another liver disease caused by a specific gene mutation that results in a faulty protein accumulating in the liver. The company is working on therapies that can be delivered directly into the body (in vivo) to correct the genetic errors causing these conditions. Initial clinical data for these liver-focused programs are anticipated in 2027. - **Cystic Fibrosis Program** Prime Medicine is also developing a gene therapy for Cystic Fibrosis (CF), a disease that affects the lungs and digestive system. CF is caused by mutations in a gene that controls the movement of salt and water in and out of cells, leading to thick, sticky mucus buildup. The company is working on an in vivo approach, meaning the therapy is delivered directly into the body, to address the genetic root of CF. This program is being developed with support from the Cystic Fibrosis Foundation, a non-profit organization dedicated to finding cures for CF. - **Hematology, Immunology & Oncology (CAR-T)** Prime Medicine is collaborating with Bristol Myers Squibb, a large pharmaceutical company, to develop a type of therapy called Prime Edited CAR-T cells. CAR-T therapy is a type of cancer treatment where a patient's own immune cells (T-cells) are genetically modified to better recognize and attack cancer cells. In this partnership, Prime Medicine's prime editing technology is used to enhance these T-cells for potential use in treating blood cancers (hematology), immune system disorders (immunology), and cancer in general (oncology). This collaboration involves developing optimized prime editing tools for these specific cell therapies. - **What management is betting on now** Prime Medicine's current strategy is to focus its resources on developing gene therapies for significant genetic liver diseases, like Wilson Disease and Alpha-1 Antitrypsin Deficiency, as well as its Cystic Fibrosis program. They are also continuing their partnership with Bristol Myers Squibb to advance Prime Edited CAR-T cell therapies. The company has deprioritized its Chronic Granulomatous Disease (CGD) programs to concentrate on these areas. Management believes that by focusing on these specific programs, they can maximize the potential of their prime editing technology to deliver one-time curative treatments for a wider range of patients. This strategic shift aims to streamline development and reduce the company's overall spending.